FDA determines that sale of product in the U.S. is 'appropriate for the protection of the public health'
Dated Dec 17, 2019, proceeding US holiday. This timing minimizes both news coverage and public discussion.
U.S. Food and Drug Administration (FDA) has found that the marketing of 22nd Century Group's proprietary Moonlight(R) and Moonlight(R) Menthol brand cigarettes are "appropriate for the protection of the public health
The FDA also issued a news release today explaining why Moonlight(R) and Moonlight(R) Menthol brand cigarettes received authorization for marketing and sales of the products in the U.S. market. In that news release, Mitch Zeller, J.D., the Director of the FDA's Center for tobacco Products, stated, "Conventional cigarettes are designed to create and sustain addiction to nicotine. In announcing the FDA's comprehensive plan to regulate tobacco and nicotine in July 2017, we noted our commitment to taking actions that will allow more addicted smokers to reduce their dependence and decrease the likelihood that future generations will become addicted to cigarettes... Today's authorization represents the first product to successfully demonstrate the potential for these types of tobacco products to help reduce nicotine dependence among addicted smokers." The FDA news release further provides that, "The agency determined that non-smokers, including youth, are also unlikely to start using the products, and those who experiment are less likely to become addicted than people who experiment with conventional cigarettes."
Dated Dec 17, 2019, proceeding US holiday. This timing minimizes both news coverage and public discussion.
Last edited: